B-0069 (Shanghai Pharmaceuticals Holding)

N/A

Report date: 2025/05/13 15:10:28

Base Information

Drug NameB-0069 (Shanghai Pharmaceuticals Holding)
Drug Alias NameRecombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1注射用重组人鼠嵌合抗CD30单克隆抗体-MCC-DM1偶联剂F0002-ADCB-006(SCP)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > SMCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-Tumor necrosis factor receptor superfamily member 8
TargetsTumor necrosis factor receptor superfamily member 8Tubulin
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Pharmaceuticals Holding Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Pharmaceuticals Holding Co LtdShanghai Crosslink Pharmaceutical R & D Co LtdShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A